JAK/STAT blockade in cHL
Ontology highlight
ABSTRACT: Here we investigated the effects of JAK/STAT pharmacological inhibition on cHL cell models using ruxolitinib, a JAK 1/2 inhibitor. We use five classical Hodgkin lymphoma cell lines: L428, L1236, L540, KMH2, L591
ORGANISM(S): Homo sapiens
PROVIDER: GSE185818 | GEO | 2021/10/15
REPOSITORIES: GEO
ACCESS DATA